Ascendis Pharma Past Earnings Performance
Past criteria checks 2/6
Ascendis Pharma has been growing earnings at an average annual rate of 17.7%, while the Biotechs industry saw earnings growing at 36.2% annually. Revenues have been growing at an average rate of 63.2% per year. Ascendis Pharma's return on equity is 101.6%, and it has net margins of 57.3%.
Key information
17.69%
Earnings growth rate
18.91%
EPS growth rate
| Biotechs Industry Growth | 17.04% |
| Revenue growth rate | 63.21% |
| Return on equity | 101.63% |
| Net Margin | 57.28% |
| Last Earnings Update | 31 Mar 2026 |
Recent past performance updates
Recent updates
Ascendis Pharma: Rare Endocrine Compounder Entering Growth Phase (Initiating Buy)
Summary Ascendis Pharma is initiated with a buy rating, reflecting its transition to a durable, commercial-stage rare endocrine franchise. ASND's valuation premium is justified by high-quality revenue growth, multiple product launches, operating leverage, and reduced financing risk. Yorvipath and Yuviwel are driving robust pipeline momentum, with Yorvipath scaling rapidly in chronic hypoparathyroidism and Yuviwel poised for expansion in achondroplasia. The next 12–18 months are catalyst-rich, with regulatory, clinical, and commercial milestones supporting the self-funded growth strategy and platform expansion. Read the full article on Seeking AlphaStatutory Earnings May Not Be The Best Way To Understand Ascendis Pharma's (NASDAQ:ASND) True Position
We didn't see Ascendis Pharma A/S' ( NASDAQ:ASND ) stock surge when it reported robust earnings recently. We think that...
Long Term TransCon Pipeline Execution Will Shape Future Cash Flows And Business Durability
Catalysts About Ascendis Pharma Ascendis Pharma focuses on developing and commercializing long-acting therapies for rare endocrine and growth disorders using its TransCon technology platform. What are the underlying business or industry changes driving this perspective?
Long Acting TransCon Therapies Will Reshape Rare Endocrine Treatment Over The Coming Years
Catalysts About Ascendis Pharma Ascendis Pharma focuses on developing and commercializing long acting therapies for rare endocrine and growth disorders using its TransCon technology platform. What are the underlying business or industry changes driving this perspective?Revenue & Expenses Breakdown
How Ascendis Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 26 | 866 | 496 | 506 | 280 |
| 31 Dec 25 | 720 | -228 | 458 | 304 |
| 30 Sep 25 | 647 | -233 | 399 | 301 |
| 30 Jun 25 | 491 | -271 | 355 | 307 |
| 31 Mar 25 | 369 | -342 | 322 | 319 |
| 31 Dec 24 | 364 | -378 | 291 | 307 |
| 30 Sep 24 | 327 | -426 | 275 | 319 |
| 30 Jun 24 | 318 | -490 | 269 | 356 |
| 31 Mar 24 | 329 | -502 | 265 | 378 |
| 31 Dec 23 | 267 | -481 | 264 | 413 |
| 30 Sep 23 | 152 | -602 | 257 | 431 |
| 30 Jun 23 | 119 | -609 | 254 | 417 |
| 31 Mar 23 | 78 | -569 | 240 | 403 |
| 01 Jan 23 | 51 | -583 | 221 | 380 |
| 30 Sep 22 | 33 | -482 | 213 | 337 |
| 30 Jun 22 | 19 | -393 | 192 | 298 |
| 31 Mar 22 | 14 | -446 | 170 | 291 |
| 31 Dec 21 | 8 | -384 | 160 | 296 |
| 30 Sep 21 | 3 | -416 | 132 | 491 |
| 30 Jun 21 | 5 | -458 | 111 | 432 |
| 31 Mar 21 | 5 | -418 | 96 | 349 |
| 31 Dec 20 | 7 | -419 | 77 | 261 |
| 30 Sep 20 | 9 | -360 | 73 | 50 |
| 30 Jun 20 | 8 | -264 | 66 | 192 |
| 31 Mar 20 | 10 | -228 | 56 | 140 |
| 31 Dec 19 | 13 | -218 | 48 | 192 |
| 30 Sep 19 | 21 | -170 | 40 | 179 |
| 30 Jun 19 | 19 | -178 | 37 | 70 |
| 31 Mar 19 | 16 | -142 | 31 | 161 |
| 31 Dec 18 | 11 | -130 | 25 | 140 |
| 30 Sep 18 | 0 | -132 | 21 | 130 |
| 30 Jun 18 | 1 | -132 | 17 | 128 |
| 31 Mar 18 | 1 | -140 | 15 | 110 |
| 31 Dec 17 | 2 | -124 | 13 | 100 |
| 30 Sep 17 | 2 | -106 | 13 | 92 |
| 30 Jun 17 | 3 | -91 | 12 | 79 |
| 31 Mar 17 | 4 | -73 | 12 | 70 |
| 31 Dec 16 | 5 | -69 | 12 | 66 |
| 30 Sep 16 | 6 | -64 | 12 | 59 |
| 30 Jun 16 | 6 | -53 | 10 | 50 |
| 31 Mar 16 | 7 | -55 | 10 | 49 |
| 31 Dec 15 | 8 | -33 | 9 | 41 |
| 30 Sep 15 | 9 | -26 | 8 | 36 |
| 30 Jun 15 | 10 | -21 | 8 | 31 |
Quality Earnings: ASND has a high level of non-cash earnings.
Growing Profit Margin: ASND became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ASND has become profitable over the past 5 years, growing earnings by 17.7% per year.
Accelerating Growth: ASND has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: ASND has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (54.5%).
Return on Equity
High ROE: Whilst ASND's Return on Equity (101.63%) is outstanding, this metric is skewed due to their high level of debt.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/10 13:26 |
| End of Day Share Price | 2026/06/10 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ascendis Pharma A/S is covered by 30 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Eliana Merle | Barclays |
| Tazeen Ahmad | BofA Global Research |
| Michelle Gilson | Canaccord Genuity |